Ju Qiu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Ju Qiu has a total of 23 co-authors. Here are the top co-authors by number of shared publications:
- Alexandra N. Jay
United States Army Medical Research Institute of Infectious Diseases, Frederick, MD 21702, USA
1 shared publication - Christoph L. Bausch
SAB Biotherapeutics, 2100 E 54th St. N, Sioux Falls, SD 57104, USA
1 shared publication - Christopher K. Cote
Bacteriology Division, United States Army Medical Research Institute of Infectious Diseases (USAMRIID), United States
1 shared publication - Christopher P. Klimko
Bacteriology Division, United States Army Medical Research Institute of Infectious Diseases, 1425 Porter Street, Fort Detrick, Frederick, MD 21702, USA
1 shared publication - Curtis R. Cline
Pathology Division, U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID), Frederick, MD, USA
1 shared publication - David P. Fetterer
Biostatistics Division, United States Army Medical Research Institute of Infectious Diseases, 1425 Porter Street, Fort Detrick, Frederick, MD 21702, USA
1 shared publication
Latest Publications
- Open Access
- 18 December 2025
- Published by Microbiology Society in Microbiology
- Vol. 171 (12) , 001637
Animal modelling with the Francisella tularensis subspecies holarctica strain OR96-0246
Tularemia is a zoonotic disease caused by Francisella tularensis . Most human cases are caused by F. tularensis ssp. tularensis (type A) or F. tularensis ssp. holarctica (type B), with the former considered more virulent. For this reason, type A isolates are often the benchmark for the testing of new vaccines or antibiotics. However, both subspecies cause considerable disease and can differ in their responsiveness to medical countermeasures. Accordingly, there is a need to identify and characterize representative type B isolates that are available to qualified research institutions to ensure the development of future vaccines or antibiotics is efficacious against both subspecies. The type B isolate OR96-0246 was identified as a strain that can address this need and was subsequently characterized. For in vitro characterization, the OR96-0246 strain was examined for growth in media and for its ability to form biofilm. As the LPS is an essential virulence factor, the O-antigen was characterized through western analysis. For future medical countermeasure testing for biodefence concerns, pneumonic challenges with animal modelling would be required. Therefore, using the OR96-0246 strain, we implemented animal models that encompassed BALB/c mice, Fischer 344 rats and cynomolgus macaques. Mice were challenged via intranasal instillation with varying doses of OR96-0246, and the LD 50 was determined to be 1 c.f.u. We progressed to Fischer 344 rats, which are a better-suited rodent model to gauge vaccine efficacy. When challenging the rats by whole body aerosolization with various doses of OR96-0246, the LD 50 was determined to be 138 c.f.u. Finally, a staircase challenge design was applied to three cynomolgus macaques, each receiving a different aerosolized dose of OR96-0246 to determine an estimated LD 50 for non-human primates (NHPs). Two out of the three NHPs succumbed to the challenge. The animal that received the lowest dose (2.1×10 4 c.f.u.) survived but did demonstrate clinical signs of infection. Samples from the challenged rats and NHPs were collected for histopathology characterization. Generally, the pathological changes observed in both models were similar, consisting primarily of multifocal bronchopneumonia in the lung and necrotic lesions in the spleen. This animal model development with type B strains of F. tularensis will be essential to properly evaluate new antimicrobials and vaccines to protect against tularemia.
- 18 December 2025
- Published by Microbiology Society in Microbiology
- Vol. 171 (12) , 001637
Open AccessAnimal modelling with the Francisella tularensis subspecies holarctica strain OR96-0246
Tularemia is a zoonotic disease caused by Francisella tularensis . Most human cases are caused by F. tularensis ssp. tularensis (type A) or F. tularensis ssp. holarctica (type B), with the former considered more virulent. For this reason, type A isolates are often the benchmark for the testing of new vaccines or antibiotics. However, both subspecies cause considerable disease and can differ in their responsiveness to medical countermeasures. Accordingly, there is a need to identify and characterize representative type B isolates that are available to qualified research institutions to ensure the development of future vaccines or antibiotics is efficacious against both subspecies. The type B isolate OR96-0246 was identified as a strain that can address this need and was subsequently characterized. For in vitro characterization, the OR96-0246 strain was examined for growth in media and for its ability to form biofilm. As the LPS is an essential virulence factor, the O-antigen was characterized through western analysis. For future medical countermeasure testing for biodefence concerns, pneumonic challenges with animal modelling would be required. Therefore, using the OR96-0246 strain, we implemented animal models that encompassed BALB/c mice, Fischer 344 rats and cynomolgus macaques. Mice were challenged via intranasal instillation with varying doses of OR96-0246, and the LD 50 was determined to be 1 c.f.u. We progressed to Fischer 344 rats, which are a better-suited rodent model to gauge vaccine efficacy. When challenging the rats by whole body aerosolization with various doses of OR96-0246, the LD 50 was determined to be 138 c.f.u. Finally, a staircase challenge design was applied to three cynomolgus macaques, each receiving a different aerosolized dose of OR96-0246 to determine an estimated LD 50 for non-human primates (NHPs). Two out of the three NHPs succumbed to the challenge. The animal that received the lowest dose (2.1×10 4 c.f.u.) survived but did demonstrate clinical signs of infection. Samples from the challenged rats and NHPs were collected for histopathology characterization. Generally, the pathological changes observed in both models were similar, consisting primarily of multifocal bronchopneumonia in the lung and necrotic lesions in the spleen. This animal model development with type B strains of F. tularensis will be essential to properly evaluate new antimicrobials and vaccines to protect against tularemia.
- Open Access
- 8 May 2023
- Published by MDPI AG in Antibodies
- Vol. 12 (2) , 33
Polyclonal Antibodies Derived from Transchromosomic Bovines Vaccinated with the Recombinant F1-V Vaccine Increase Bacterial Opsonization In Vitro and Protect Mice from Pneumonic Plague
Plague is an ancient disease that continues to be of concern to both the public health and biodefense research communities. Pneumonic plague is caused by hematogenous spread of Yersinia pestis bacteria from a ruptured bubo to the lungs or by directly inhaling aerosolized bacteria. The fatality rate associated with pneumonic plague is significant unless effective antibiotic therapy is initiated soon after an early and accurate diagnosis is made. As with all bacterial pathogens, drug resistance is a primary concern when developing strategies to combat these Yersinia pestis infections in the future. While there has been significant progress in vaccine development, no FDA-approved vaccine strategy exists; thus, other medical countermeasures are needed. Antibody treatment has been shown to be effective in animal models of plague. We produced fully human polyclonal antibodies in transchromosomic bovines vaccinated with the recombinant F1-V plague vaccine. The resulting human antibodies opsonized Y. pestis bacteria in the presence of RAW264.7 cells and afforded significant protection to BALB/c mice after exposure to aerosolized Y. pestis. These data demonstrate the utility of this technology to produce large quantities of non-immunogenic anti-plague human antibodies to prevent or possibly treat pneumonic plague in human.
- 8 May 2023
- Published by MDPI AG in Antibodies
- Vol. 12 (2) , 33
Open AccessPolyclonal Antibodies Derived from Transchromosomic Bovines Vaccinated with the Recombinant F1-V Vaccine Increase Bacterial Opsonization In Vitro and Protect Mice from Pneumonic Plague
Plague is an ancient disease that continues to be of concern to both the public health and biodefense research communities. Pneumonic plague is caused by hematogenous spread of Yersinia pestis bacteria from a ruptured bubo to the lungs or by directly inhaling aerosolized bacteria. The fatality rate associated with pneumonic plague is significant unless effective antibiotic therapy is initiated soon after an early and accurate diagnosis is made. As with all bacterial pathogens, drug resistance is a primary concern when developing strategies to combat these Yersinia pestis infections in the future. While there has been significant progress in vaccine development, no FDA-approved vaccine strategy exists; thus, other medical countermeasures are needed. Antibody treatment has been shown to be effective in animal models of plague. We produced fully human polyclonal antibodies in transchromosomic bovines vaccinated with the recombinant F1-V plague vaccine. The resulting human antibodies opsonized Y. pestis bacteria in the presence of RAW264.7 cells and afforded significant protection to BALB/c mice after exposure to aerosolized Y. pestis. These data demonstrate the utility of this technology to produce large quantities of non-immunogenic anti-plague human antibodies to prevent or possibly treat pneumonic plague in human.